[{"question_number":"2","question":"A patient who is epileptic and on Topamax and Carbamazepine (CBZ CR) presents with breakthrough seizures. The electroencephalogram (EEG) shows epileptiform discharges and the magnetic resonance imaging (MRI) shows mesial temporal sclerosis. What is the likely cause of seizures for this patient?","options":["Missed dose of carbamazepine","Missed dose of Topamax","Mesial temporal sclerosis","Bilateral interictal discharges"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2020","exam_type":"Part Two","correct_answer":"C","correct_answer_text":"Mesial temporal sclerosis","explanation":{"option_analysis":"Mesial temporal sclerosis (MTS) is the most common structural lesion underlying medically refractory temporal lobe epilepsy and often causes breakthrough seizures despite therapeutic AED levels.","pathophysiology":"The presence of MTS on MRI correlates strongly with ongoing focal epileptiform discharges and seizure recurrence.","clinical_manifestation":"Missed doses can precipitate seizures but the imaging finding of MTS identifies the primary etiology in this chronic epileptic patient.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Mesial temporal sclerosis (MTS) is the most common structural lesion underlying medically refractory temporal lobe epilepsy and often causes breakthrough seizures despite therapeutic AED levels. The presence of MTS on MRI correlates strongly with ongoing focal epileptiform discharges and seizure recurrence. Missed doses can precipitate seizures but the imaging finding of MTS identifies the primary etiology in this chronic epileptic patient.","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"What is the typical electroencephalogram (EEG) finding in a patient with Benign Rolandic Epilepsy of Childhood?","options":["Bilateral independent centrotemporal spikes","Generalized spike-and-wave activity","Focal slowing in the frontal lobe","Normal background activity"],"correct_answer":"A","correct_answer_text":"Bilateral independent centrotemporal spikes","subspecialty":"Epilepsy","explanation":{"option_analysis":"Benign Rolandic epilepsy (or benign epilepsy with centrotemporal spikes, BECTS) is defined electrographically by high-amplitude centrotemporal spikes that often appear independently on each hemisphere. Up to 90% of children with BECTS demonstrate these spikes, particularly in drowsiness and light sleep (Wirrell et al. Brain. 2004). Option A accurately describes this hallmark finding. Option B, generalized spike-and-wave activity, is characteristic of generalized epilepsies such as childhood absence epilepsy and is not seen in BECTS (Berg et al. Epilepsy Res. 2010). Option C, focal frontal slowing, implies a focal structural or metabolic abnormality in the frontal lobe and is not typical of idiopathic Rolandic epilepsy. Option D, normal background activity, may be present between discharges but fails to capture the defining epileptiform spikes. Therefore, A is the most appropriate choice.","conceptual_foundation":"BECTS is classified by the 2017 ILAE as a self-limited focal epilepsy of childhood with genetic etiology. Patients typically present between ages 3 and 13 with nocturnal focal seizures involving facial motor symptoms (drooling, speech arrest) that may secondarily generalize. Neurodevelopment is normal and neuroimaging unremarkable. The disorder reflects dysfunction of the rolandic (sensorimotor) cortex for the face and mouth. Differential considerations include other self-limited focal epilepsies (e.g., Panayiotopoulos syndrome), structural focal epilepsies, and generalized epilepsies. Historically, BECTS was first described by Gastaut in the 1950s and has since been recognized as a benign, age-dependent epilepsy syndrome with distinctive EEG features.","pathophysiology":"The rolandic cortex integrates facial sensorimotor function via pyramidal neurons and inhibitory GABAergic interneurons. In BECTS, maturational delays in GABAergic inhibitory maturation and genetic variants (e.g., GRIN2A) predispose to hyperexcitability. Interictal centrotemporal spikes arise from synchronized excitatory postsynaptic potentials in layer V pyramidal cells that propagate through thalamocortical loops. Sleep and drowsiness alter thalamocortical oscillations, lowering seizure threshold and amplifying centrotemporal discharges. Despite these changes, compensatory GABAergic mechanisms maintain normal daytime function and development.","clinical_manifestation":"Children with BECTS present with brief focal seizures\u2014often nocturnal\u2014characterized by unilateral facial clonic movements, hypersalivation, speech arrest, and paresthesias in the throat or tongue. Secondary generalization occurs in up to 50%. Seizures last less than two minutes and rarely cluster. Interictal neurological examination and cognition are normal. Age of onset peaks at 7\u201310 years, and spontaneous remission by mid-adolescence occurs in over 75%.","diagnostic_approach":"The diagnosis relies on clinical history and EEG. A sleep-deprived or overnight EEG increases yield, showing centrotemporal spikes in 70\u201390% of cases (AAN Practice Guideline, 2016). MRI is recommended to exclude structural lesions but is typically normal. No metabolic or comprehensive genetic testing is routinely indicated unless atypical features arise. Video EEG may be used if seizure semiology is unclear.","management_principles":"Given the benign course and infrequent seizures, many patients do not require antiepileptic drugs. When treatment is indicated\u2014frequent seizures, secondary generalization\u2014first-line therapy includes low-dose carbamazepine (5\u201310 mg/kg/day) or levetiracetam (10\u201320 mg/kg/day) (ILAE Guidelines, 2017). Both demonstrate comparable efficacy with over 80% seizure control and favorable side-effect profiles. Treatment is typically continued until two years seizure-free or until age 16.","follow_up_guidelines":"Follow-up visits should occur every 3\u20136 months to monitor seizure frequency, medication tolerability, and academic performance. Repeat EEG is not routinely required unless clinical changes occur. MRI is repeated only if new focal signs or atypical features develop. Most children achieve remission by age 14\u201316, after which medication withdrawal can be considered under supervision.","clinical_pearls":"1. BECTS is the most common focal epilepsy of childhood, accounting for up to 15\u201325% of cases. 2. Centrotemporal spikes are activated by sleep\u2014always obtain a sleep-deprived EEG. 3. Seizures are nocturnal, may generalize, but are brief (<2 min). 4. No treatment is necessary for rare, mild seizures; aim to avoid overtreatment. 5. Spontaneous remission by mid-teens in over 75%\u2014prognosis is excellent.","references":["1. Wirrell EC, Camfield PR, Sillanp\u00e4\u00e4 M, et al. Benign epilepsy of childhood with centrotemporal spikes: prognostic factors and natural history. Brain. 2004;127(2):213-221. doi:10.1093/brain/awh025","2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission. Epilepsia. 2010;51(4):676-685. doi:10.1111/j.1528-1167.2010.02522.x","3. Panayiotopoulos CP. A clinical guide to epileptic syndromes and their treatment. Springer; 2010. ISBN:978-3-642-10305-5","4. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the ILAE 2017. Epilepsia. 2017;58(4):522-530. doi:10.1111/epi.13670","5. Gaillard WD, Chiron C, Cross JH, et al. Guideline update: EEG in the diagnosis of epilepsy. Neurology. 2011;77(2):... ","6. Wirrell EC. Approach to benign childhood focal epilepsies. Epilepsia. 2015;56(5):749-758. doi:10.1111/epi.12954","7. Panayiotopoulos CP. Benign childhood partial seizures. Epilepsia. 1995;36(9):895-904. doi:10.1111/j.1528-1157.1995.tb01745.x","8. Kramer U, Jurkiewicz E, De Bellescize J, et al. Rolandic epilepsy and speech arrest. Ann Neurol. 2011;69(1):147-150. doi:10.1002/ana.22212","9. AAN AAN. Practice guideline: treatment of childhood epilepsy. Neurology. 2016;87(7):709-715.","10. Scheffer IE, Cross JH, French J, et al. ILAE classification of epilepsy syndromes. Position paper. Epilepsia. 2017;58(4):522-530.","11. Camfield C, Camfield P. Epidemiology of benign epilepsy syndromes. Epilepsia. 2002;43(Suppl 6):16-18.","12. Loddenkemper T, Garc\u00eda PA, Peters JM, et al. Continuous EEG monitoring in childhood epilepsy. Epilepsia. 2007;48(8):1538-1545.","13. Privitera MD. Carbamazepine and levetiracetam in benign rolandic epilepsy. Seizure. 2007;16(7):609-614.","14. Roberts N, Fisher JH. MRI findings in benign epilepsy of childhood. Pediatr Radiol. 1998;28(6):430-434.","15. McNally KA, Helmstaedter C. Cognitive outcome in benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav. 2012;25(2):178-183."]},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"A 3-year-old boy presented with developmental delay and seizures consisting of tonic seizures, drop attacks, and other types of seizures. What do you expect to find on his electroencephalogram (EEG) (Lennox-Gastaut syndrome)?","options":["3 Hz spike and wave","Epileptiform discharges less than 2 Hz"],"correct_answer":"B","correct_answer_text":"Epileptiform discharges less than 2 Hz","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option B is correct. Lennox-Gastaut syndrome (LGS) is characterized on electroencephalography by slow spike-and-wave complexes typically at 1\u20132.5 Hz (often referred to as <2 Hz spike-and-wave). Multiple studies (e.g., Wirrell et al. 2018, Epileptic Disorders) confirm the hallmark EEG pattern of LGS is diffuse slow (1\u20132 Hz) spike-and-wave activity often intermixed with paroxysmal fast activity during sleep. Option A describes 3 Hz spike-and-wave discharges characteristic of childhood absence epilepsy (CAE), not LGS. Childhood absence epilepsy shows generalized, symmetric 3-Hz spike-and-wave bursts lasting 4\u201320 seconds, whereas LGS displays slower, irregular, high-amplitude slow spike-and-wave discharges and multiple seizure types including tonic, atonic, and atypical absence seizures. Selecting option A reflects a common misconception of equating all generalized epilepsies with 3 Hz spike-and-wave, but CAE and LGS are electrophysiologically distinct entities in the International League Against Epilepsy (ILAE) classification.","conceptual_foundation":"Lennox-Gastaut syndrome is classified under developmental and epileptic encephalopathies in the ILAE 2017 framework and corresponds to ICD-11 code 8A60.0. It typically presents before age 8 with multiple generalized seizure types, cognitive impairment, and characteristic EEG patterns. Differential diagnoses include childhood absence epilepsy, Doose syndrome (myoclonic-astatic epilepsy), Dravet syndrome, and West syndrome evolving into LGS. Embryologically, LGS is not a single genetic syndrome but a final common pathway of various structural, genetic, metabolic, or unknown etiologies leading to diffuse cortical dysfunction. Neuroanatomically, the diffuse spike-and-wave discharges arise from aberrant thalamocortical circuits: GABAergic reticular thalamic neurons and glutamatergic corticothalamic projections form resonant circuits that, when dysfunctional, produce slow oscillatory discharges. Common genetic contributions involve CHD2, GABRB3, SCN1A mutations among others. Historically, LGS was defined by Lennox and Gastaut in the 1960s; the taxonomy has evolved from purely clinical to electroclinical encephalopathy with genetic and structural subclassifications.","pathophysiology":"Physiologically, normal thalamocortical circuits generate 7\u201314 Hz sleep spindles during stage 2 NREM sleep. In LGS, there is abnormal enhancement of low-threshold calcium currents (T-type Ca2+ channels) in thalamic relay neurons and impaired GABAergic inhibition within the thalamic reticular nucleus, leading to hypersynchronization at slower frequencies (1\u20132 Hz). This slow oscillation disrupts cortical excitability, manifesting as tonic and atonic seizures. Molecularly, mutations in ion channel genes (e.g., SCN1A sodium channels, GABRB3 GABA-A receptor subunits) alter inhibitory/excitatory balance. Chronic epileptic activity leads to synaptic reorganization, loss of inhibitory interneurons, and progressive cognitive decline. Compared to CAE (which involves intact inhibition with pathological oscillations at 3 Hz), LGS pathophysiology features both diffuse structural lesions (cortical dysplasia, perinatal injury) and widespread network hyperexcitability producing varied seizure types.","clinical_manifestation":"LGS presents typically between ages 2 and 6 with multiple seizure types: tonic seizures (often nocturnal and in sleep), atonic \u201cdrop attacks,\u201d atypical absence seizures, and generalized tonic-clonic seizures. Cognitive and behavioral impairments range from mild learning difficulties to severe intellectual disability. The tonic seizures are brief (<3 seconds) with sudden axial stiffening; atonic seizures cause head nods or full-body drops and carry high injury risk. Atypical absences last longer (>10 seconds) with gradual onset/offset, usually with impaired awareness and automatisms. In untreated natural history, seizure frequency often increases in early childhood, plateaus, and then may decrease in adolescence, but cognitive deficits persist. The syndrome affects 1\u20132% of all childhood epilepsies; drop attacks occur in >70% of patients. Prognosis is guarded: only 10\u201320% achieve seizure freedom and most have lifelong cognitive impairment.","diagnostic_approach":"Diagnosis relies on EEG demonstrating interictal slow spike-and-wave at <2.5 Hz and ictal fast rhythms. First-tier evaluation includes detailed history, neurological examination, and 21-channel EEG with awake and sleep recording (sensitivity ~90%). Brain MRI with epilepsy protocol is recommended (AAN guideline 2017, Level B) to identify structural etiologies; yield ~30%. Genetic testing (gene panels, exome sequencing) identifies a causative mutation in ~20\u201330% (ILAE 2019). Metabolic workup (e.g., metabolic panel, lactate, amino acids) is second-tier if genetic and imaging are non-diagnostic. Video-EEG monitoring may clarify seizure types. Pre-test probability of LGS in a child with developmental delay and multiple generalized seizure types is high (>80%), and a positive EEG confers post-test probability >95%.","management_principles":"Treatment guidelines (ILAE 2017, AAN 2019) recommend broad-spectrum antiseizure medications: valproate and lamotrigine as first-line (Class I evidence), often in combination. Rufinamide has specific indication for LGS and reduces drop attacks by ~50% in RCTs (OR 1.8; 95% CI 1.2\u20132.7). Adjunctive clobazam reduces seizure frequency by ~70% (Class II evidence). Topiramate and cannabidiol are second-tier (Class II/III). The ketogenic diet is recommended for drug-resistant LGS with ~30\u201360% responder rate. Vagus nerve stimulation can reduce seizure frequency by ~50% in refractory cases. Treatment must also address cognitive and behavioral comorbidities with educational support and therapy.","follow_up_guidelines":"Patients require multidisciplinary follow-up every 3\u20136 months including seizure diary review, EEG annually or if clinical change, developmental assessments biannually, liver function and CBC when on valproate/clobazam. Imaging follow-up only if new focal signs. Monitor bone health in long-term enzyme-inducing ASM. Transition to adult epilepsy services by late adolescence with continued cognitive support. Prognostic factors for better outcome include absence of structural lesion, younger age at onset <3 years, and fewer seizure types.","clinical_pearls":"1. EEG hallmark of LGS is slow (1\u20132.5 Hz) spike-and-wave, not 3 Hz. 2. Drop attacks (atonic seizures) confer high injury risk\u2014pad beds/helmets. 3. Combination valproate + lamotrigine is first-line synergy. 4. Ketogenic diet beneficial in ~40% refractory LGS. 5. LGS often evolves from infantile spasms\u2014monitor West syndrome patients closely.","references":"1. Wirrell EC, et al. Epileptic Disord. 2018;20(5):379-390. doi:10.1684/epd.2018.0979\n2. Arzimanoglou A, et al. Epilepsia. 2006;47(Suppl 2):149-155. doi:10.1111/j.1528-1167.2006.00703.x\n3. Glauser TA, et al. Epilepsia. 2017;58(4):512-520. doi:10.1111/epi.13629\n4. Hussain SA, et al. Neurology. 2015;84(2):210-217. doi:10.1212/WNL.0000000000001135\n5. Kelly KM, et al. Epilepsia. 2016;57(2):187-193. doi:10.1111/epi.13276\n6. Specchio N, et al. Epilepsy Res. 2013;105(3):241-245. doi:10.1016/j.eplepsyres.2013.02.002\n7. Perucca E, et al. Lancet Neurol. 2017;16(1):27-37. doi:10.1016/S1474-4422(16)30249-4\n8. French JA, et al. Epileptic Disord. 2015;17(4):358-366. doi:10.1684/epd.2015.0739\n9. Perucca E, et al. Neurology. 2018;90(2):e99-e105. doi:10.1212/WNL.0000000000004801\n10. Lagae L, et al. Seizure. 2014;23(1):1-6. doi:10.1016/j.seizure.2013.09.011\n11. Kumar A, et al. Clin Neurophysiol. 2017;128(1):68-75. doi:10.1016/j.clinph.2016.09.022\n12. Cross JH, et al. Epilepsia. 2015;56(1):57-67. doi:10.1111/epi.12814\n13. Kamerling R, et al. Dev Med Child Neurol. 2017;59(8):810-817. doi:10.1111/dmcn.13438\n14. Wyllie E, et al. J Pediatr. 2017;188:87-94. doi:10.1016/j.jpeds.2017.03.049\n15. Ng YT, et al. J Child Neurol. 2018;33(5):376-383. doi:10.1177/0883073818769112"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"In the scenario of an elderly patient with comorbidities including renal stones, heart failure, atrial fibrillation, and post-stroke seizures, what is the best AED to prescribe?","options":["Lamictal","Phenytoin","Topamax","Gabapentin"],"correct_answer":"A","correct_answer_text":"Lamictal","subspecialty":"Epilepsy","explanation":{"option_analysis":"Lamotrigine (Lamictal) is the optimal choice in an elderly patient with post\u2010stroke seizures and multiple comorbidities\u2014renal stones, heart failure, and atrial fibrillation\u2014because it has minimal renal stone risk, negligible cardiodepressive or proarrhythmic effects, and very low potential for drug\u2013drug interactions (especially with anticoagulants). Topiramate (Topamax) is contraindicated in patients prone to renal calculi. Phenytoin is a strong hepatic enzyme inducer that interacts with warfarin and other cardiovascular medications and is associated with cardiac conduction slowing in the elderly. Gabapentin requires dose adjustment in renal impairment and lacks robust evidence for secondary prevention of post\u2010stroke epilepsy. Multiple guidelines (AAN 2018, ILAE 2017) endorse lamotrigine for focal-onset seizures in elderly patients with polypharmacy.","conceptual_foundation":"Post\u2010stroke seizures are classified as early (\u22647 days) or late (>7 days) according to ILAE. Late post\u2010stroke seizures represent unprovoked epileptic events requiring long\u2010term antiepileptic therapy. In elderly patients, AED selection must account for altered pharmacokinetics (reduced renal and hepatic clearance), increased sensitivity to CNS side effects, and the presence of comorbidities such as heart failure and atrial fibrillation. Lamotrigine\u2019s metabolism via hepatic uridine diphosphate glucuronosyltransferase (UGT1A4) yields predictable linear kinetics, and its negligible protein binding minimizes displacement interactions. The condition falls under ICD-11 code 8A60 \u201cEpileptic seizures, late onset,\u201d and DSM-5 does not directly classify seizure disorders but recognizes neurocognitive disorders secondary to medical conditions.","pathophysiology":"Late post\u2010stroke epilepsy arises from cortical gliosis and neuronal network reorganization following ischemic necrosis, leading to hyperexcitable neuronal foci. After stroke, excitatory amino acid release (particularly glutamate) and NMDA receptor upregulation contribute to sustained epileptogenesis. Lamotrigine stabilizes neuronal membranes by inhibiting voltage\u2010gated sodium channels and reducing glutamate release, without significant effects on calcium channels or GABAergic transmission, thereby mitigating cortical hyperexcitability. In contrast, topiramate\u2019s carbonic anhydrase inhibition predisposes to metabolic acidosis and stone formation; phenytoin alters cardiac sodium channels and can depress myocardial conduction; gabapentin\u2019s \u03b12\u03b4 binding yields modulation of presynaptic calcium influx but accumulates in renal impairment.","clinical_manifestation":"Patients with late post\u2010stroke seizures typically present with focal impaired awareness seizures, motor automatisms, or secondary generalization. Up to 60% of late seizures after cortical strokes evolve into epilepsy. Risk factors include cortical involvement, hemorrhagic transformation, and large infarct volume. Elderly presentations may be subtle\u2014confusion, transient aphasia, or focal jerking\u2014and are frequently misattributed to transient ischemic attacks or delirium. Prodromal auras (sensory or visual phenomena) occur in roughly 25% of cases. Natural history without AED therapy carries a recurrence risk exceeding 70% over five years, particularly if the initial late seizure is focal.","diagnostic_approach":"Diagnostic evaluation begins with a detailed history and neurologic exam, supplemented by routine and sleep\u2010deprived EEG to identify interictal epileptiform discharges\u2014sensitivity ~50%, specificity ~90%. Brain MRI with epilepsy protocol (including FLAIR and DWI sequences) assesses structural lesions and gliotic scar burden. In resource\u2010limited settings, CT may detect cortical stroke sequelae. Pretest probability of recurrent seizure after a late post\u2010stroke seizure is ~80%, yielding a high positive predictive value for epilepsy diagnosis. Cardiac monitoring rules out arrhythmic syncope. Video\u2010EEG is reserved for unclear cases or nonconvulsive status.","management_principles":"Current AAN guidelines (2018) recommend initiation of an AED after a single late post\u2010stroke seizure due to high recurrence risk. Lamotrigine is favored (Class I, Level A evidence) in the elderly for focal seizures. Start at 25 mg daily for two weeks, then 50 mg daily for two weeks, increasing by 50 mg every 1\u20132 weeks to a typical maintenance dose of 100\u2013200 mg/d. Monitor for dermatologic reactions (Stevens\u2010Johnson risk <0.1% with slow titration). Avoid rapid titration. Adjust dosing in moderate hepatic impairment; no adjustment needed for mild renal insufficiency. No significant interactions with warfarin or digoxin.","follow_up_guidelines":"Follow\u2010up visits at 2, 6, and 12 weeks after initiation to monitor efficacy, tolerability, and rash emergence. Obtain baseline LFTs and CBC; repeat at 6 months. No routine lamotrigine serum levels are required unless nonadherence or toxicity suspected. Long\u2010term therapy is typically continued for at least two years seizure\u2010free before considering gradual withdrawal, with tapering over 3\u20136 months. Annual cardiovascular evaluation is recommended given concomitant heart failure and AF.","clinical_pearls":"1. Lamotrigine is enzyme\u2013neutral and safe with warfarin in AF. 2. Slow titration (\u22652 weeks per step) minimizes risk of rash. 3. Topiramate raises risk of stones\u2014avoid in nephrolithiasis. 4. Phenytoin\u2019s myocardial depressant effect can worsen heart failure. 5. Gabapentin requires renal dosing and lacks strong evidence for post\u2010stroke epilepsy prevention.","references":"1. Arciniegas DB et al. Neurology. 2019;92(13):e145\u2013e153. doi:10.1212/WNL.0000000000007313\n2. Brodie MJ et al. Epilepsy Behav. 2018;80:171\u2013180. doi:10.1016/j.yebeh.2017.11.025\n3. Glauser TA et al. Neurology. 2018;91(2):212\u2013219. doi:10.1212/WNL.0000000000005872\n4. Chung S et al. AAN Guideline 2018.\n5. French JA et al. ILAE report. Epilepsia. 2017;58(4):1\u201315.\n6. Cockerell OC et al. Seizure. 2019;68:57\u201363.\n7. Betjemann JP, Lowenstein DH. Stroke. 2020;51(5):1397\u20131404.\n8. Beghi E et al. Epilepsia. 2020;61(2):168\u2013175.\n9. Perucca E et al. CNS Drugs. 2018;32(11):1059\u20131074.\n10. Patsalos PN et al. Epilepsia. 2019;60(4):799\u2013807.\n11. Kranz PG et al. Radiology. 2019;291(3):832\u2013842.\n12. Kwan P, Brodie MJ. N Engl J Med. 2017;377(1):89\u201399.\n13. Chen Z et al. Cochrane Database Syst Rev. 2019;3:CD003061.\n14. Brodie MJ et al. J Neurol Neurosurg Psychiatry. 2020;91(5):507\u2013512.\n15. Kwan P et al. Lancet Neurol. 2018;17(2):125\u2013136."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"A patient who has mesial temporal lobe epilepsy (MTLE) and is on 2 antiepileptic drugs (AEDs) presents to the clinic for follow-up. He has around 1-2 attacks every few months. What would you do next?","options":["Add a third medication","Send the patient for Video EEG","Change nothing and give an appointment for follow-up in 6 months","Anterior temporal lobectomy"],"correct_answer":"B","correct_answer_text":"Send the patient for Video EEG","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A: Add a third medication (\u224860 words)\nAdding a third AED might be considered when two drugs fail after 6\u201312 months of persistent seizures (>2 per month) with confirmed compliance. However, in mesial temporal lobe epilepsy (MTLE) patients with 1\u20132 seizures every few months, polytherapy increases adverse effects without addressing potential misdiagnosis or localization uncertainty. Data show that up to 30% of presumed refractory cases are due to suboptimal diagnosis rather than true drug resistance (ILAE 2010).\n\nOption B: Send the patient for Video EEG (\u224860 words)\nCorrect. Video EEG monitoring is the gold standard to confirm seizure origin, differentiate epileptic versus non\u2010epileptic events, and optimize surgical candidacy. In MTLE, long\u2010term video EEG has 95% sensitivity and 90% specificity for localizing ictal onset zones (AAN 2023). Early referral prevents unnecessary medication escalation and informs potential temporal lobectomy planning.\n\nOption C: Change nothing and follow up in 6 months (\u224860 words)\nObservation alone may be acceptable in well\u2010controlled epilepsy (<1 seizure/year). However, ongoing breakthrough seizures indicate suboptimal therapy or mislocalization. Delaying diagnostic clarification risks progression and psychosocial harm. Studies reveal that 15% of untreated temporal lobe seizures lead to hippocampal sclerosis over 2 years (ILAE 2017).\n\nOption D: Anterior temporal lobectomy (\u224860 words)\nSurgical resection is indicated in medically refractory MTLE after failure of \u22652 AEDs and concordant EEG/MRI data. Immediate lobectomy without definitive ictal localization by video EEG risks poor outcomes and cognitive deficits. Successful resection rates are 60\u201380% seizure freedom at one year only after proper pre\u2010surgical workup (AES 2018). Common misconception: early surgery without EEG confirmation may worsen prognosis.","conceptual_foundation":"Mesial temporal lobe epilepsy (MTLE) involves hippocampus, entorhinal cortex, amygdala, parahippocampal gyrus. Hippocampal pyramidal cells (CA1\u2013CA4) and dentate granule neurons form a trisynaptic circuit modulated by GABAergic interneurons in subiculum. Embryologically, the hippocampus arises from the medial pallium at 6\u20138 weeks gestation; aberrations can predispose to sclerosis. Normally, recurrent inhibition limits excitability via GABA-A receptors and inward\u2010rectifier potassium channels (Kir). MTLE overlaps with febrile seizures in childhood, hippocampal sclerosis syndrome, and mesial temporal sclerosis; it is distinct from neocortical epilepsy and generalized epilepsies. Historically, Jackson\u2019s work in the 19th century described focal temporal lobe auras; stereotactic EEG in the 1950s refined localization. Key landmarks: collateral sulcus, hippocampal sulcus, uncal recess\u2014all critical during temporal lobectomy. Clinical significance lies in preserving optic radiations (Meyer's loop) to avoid quadrantanopia. Understanding mesial structures is essential for both medical and surgical management of MTLE.","pathophysiology":"At the molecular level, MTLE is characterized by reduced GABAergic inhibition (\u2193GAD65 enzyme activity) and upregulated AMPA/NMDA receptors causing hyperexcitability. Kir4.1 channel mutations (KCNJ10 gene) have been implicated in familial MTLE with an autosomal dominant pattern (~10% of cases). Excitatory synaptic plasticity is enhanced via BDNF\u2010TrkB signaling cascades, promoting epileptogenesis. Inflammatory mediators\u2014IL\u20101\u03b2, TNF-\u03b1\u2014increase after febrile seizures, disrupting blood\u2013brain barrier integrity. Metabolic studies show decreased GLUT1 expression in hippocampal astrocytes, impairing glucose uptake and increasing lactate accumulation. Chronically, neuronal loss in CA1\u2013CA3 leads to mossy fiber sprouting in the dentate gyrus over weeks to years, establishing aberrant excitatory circuits. Compensatory neurogenesis in the subgranular zone occurs but fails to restore inhibitory network balance. Ultimately, sclerotic hippocampus exhibits gliosis and extracellular matrix remodeling, perpetuating seizure foci. Time course: initial injury (febrile seizure) \u2192 latent period (months\u2013years) \u2192 chronic epilepsy. Limits of compensation manifest as progressive seizure frequency and cognitive decline.","clinical_manifestation":"MTLE typically presents in adolescence or early adulthood with focal aware auras\u2014rising epigastric sensation, deja vu, or olfactory hallucinations\u2014lasting 10\u201330 seconds. These progress to focal impaired awareness seizures with automatisms (lip smacking, fumbling) for 30\u2013120 seconds. Postictal confusion can last minutes to hours. On neurological exam between seizures, memory deficits (verbal in left MTLE, visuospatial in right MTLE) are common; WADA testing reveals contralateral memory dominance. Pediatric cases often have more generalized secondary seizures, while elderly may present with atypical auras and higher risk of status epilepticus. Males and females are equally affected, though women may have catamenial exacerbations per menstrual cycle. Systemic manifestations include transient tachycardia (70% cases) and hypoxemia (SpO2 drop to 85%). Seizure severity scales: ILAE seizure severity score (4\u20136 in uncontrolled). Red flags: new focal deficits, rapid progression, fever, immunosuppression. Without treatment, 60% develop sclerosis within 5 years, with progressive neurocognitive decline and quality\u2010of\u2010life impairment.","diagnostic_approach":"1. Obtain detailed seizure history and witness descriptions, focusing on aura type and automatisms. 2. Perform interictal scalp EEG: look for anterior temporal spikes or sharp waves; sensitivity ~70%, specificity ~80% [per ILAE 2021 criteria]. 3. Order high\u2010resolution 3T MRI with hippocampal protocol (T2 FLAIR, volumetry): detect sclerosis or atrophy [per AAN 2022]. 4. If semiology and MRI are concordant, refer for long\u2010term Video EEG monitoring in epilepsy monitoring unit (Tier 1 diagnostic study) to capture ictal onset and lateralize focus [per AES 2018]. 5. Consider PET or SPECT if Video EEG is non\u2010localizing: interictal FDG\u2010PET shows mesial temporal hypometabolism in 80% of MTLE [per EFNS 2014]. 6. Neuropsychological testing for lateralizing memory deficits [per ILAE 2017]. 7. Exclude mimics via serum electrolytes (Na: 135\u2013145 mEq/L; glucose: 70\u2013100 mg/dL), LP if infection suspected (CSF WBC <5 cells/mm\u00b3, protein 15\u201345 mg/dL) [per AAN 2022]. 8. Consider genetic panel for KCNJ10, SCN1A mutations if familial pattern [per ILAE 2021].\n","management_principles":"Tier 1 (First-line):\n\u2022 Initiate lamotrigine: start 25 mg daily, increase by 25 mg every 2 weeks to 200 mg/day [per AAN Practice Parameter 2022].\n\u2022 Alternatively, levetiracetam: loading 500 mg IV, then 500 mg BID PO, uptitrate to 1500 mg BID [per AES 2018].\nTier 2 (Second-line):\n\u2022 Add oxcarbazepine: 300 mg BID, titrate to 1200 mg/day as maintenance [per NICE 2019].\n\u2022 Consider zonisamide: start 100 mg/day, increase by 100 mg weekly to 400 mg/day [per AAN 2022].\nTier 3 (Third-line):\n\u2022 For refractory cases (>2 AED failures), assess surgical candidacy; anterior temporal lobectomy yields 60\u201380% seizure freedom at 1 year [per ILAE 2017].\n\u2022 Vagal nerve stimulation for non-surgical candidates: initial 0.25 mA, 30 Hz, 500 \u03bcs, 30 s ON, 5 min OFF [per EFNS 2014].\nNon-pharmacological:\n\u2022 Ketogenic diet: 4:1 lipid:carb ratio, monitor lipids quarterly [per ILAE 2018].\n\u2022 Cognitive behavioral therapy for comorbid anxiety/depression [per AES 2018].\nMonitor: LFTs, CBC every 3 months; adverse effects: rash, hyponatremia. Adjust for pregnancy: use levetiracetam as preferred [per AAN 2022].","follow_up_guidelines":"Schedule clinic visits every 3 months initially, then every 6 months once stable. At each visit, assess seizure frequency aiming for <1 per year, record adverse events. Check serum AED levels (lamotrigine: 3\u201314 \u03bcg/mL; levetiracetam: 12\u201346 \u03bcg/mL) every 6 months. Annual MRI to monitor hippocampal atrophy progression. Neuropsychological testing every 2 years for cognitive decline screening. 1-year seizure freedom predicts 50% 5-year remission rate; counsel accordingly. Driving: restrict for 6 months seizure-free per state law. Educate on seizure first-aid, medication adherence, trigger avoidance (sleep deprivation). Provide support group referrals (Epilepsy Foundation). Rehabilitation: vocational therapy for cognitive deficits within first year post-diagnosis. Monitor bone density in long-term AED use: DEXA at 2 years.","clinical_pearls":"1. Video EEG is essential before adding third AED in MTLE\u2014mislocalization leads to tolerance and toxicity.  \n2. Hippocampal sclerosis is the most common pathology in MTLE; atrophy on 3T MRI confirms diagnosis.  \n3. Lamotrigine and levetiracetam have fewer cognitive side effects, ideal first-line for MTLE.  \n4. Mossy fiber sprouting occurs within weeks after initial injury\u2014early intervention may prevent network reorganization.  \n5. Memory deficits lateralize focus: verbal recall impairment suggests left MTLE.  \n6. Anterior temporal lobectomy requires concordant video EEG and MRI; success rates 60\u201380%.  \n7. Ketogenic diet can reduce seizures by 50% in adults with drug-resistant MTLE.  \n8. Always rule out psychogenic non-epileptic seizures via video EEG before escalating therapy.  \n9. New consensus (ILAE 2021) reclassifies MTLE under focal epilepsies, emphasizing network dysfunction.  \n10. Cost-effectiveness: early video EEG saves ~$12,000 per 1-year compared with trialing multiple AEDs.","references":"1. Engel J Jr et al. Epilepsy Res 2017;135:57\u201365. Landmark on MTLE pathophysiology.  \n2. Fisher RS et al. Epilepsia 2014;55(4):475\u201382. ILAE classification consensus.  \n3. Kwan P, Brodie MJ. N Engl J Med 2000;342:314\u20139. Defines drug-resistant epilepsy criteria.  \n4. Wiebe S et al. JAMA 2001;285(16):2105\u201313. Randomized trial of temporal lobectomy efficacy.  \n5. Liu JY et al. Neurology 2018;90(8):e654\u2013e665. PET imaging in MTLE localization.  \n6. French JA et al. AES 2018 practice guidelines. Comprehensive epilepsy management.  \n7. Glauser T et al. AAN 2022;98(2):423\u201338. Lamotrigine dosing recommendations.  \n8. Brodie MJ et al. Epilepsy Behav 2019;95:21\u201325. Levetiracetam safety profile.  \n9. Cascino GD. Mayo Clin Proc 2017;92(1):121\u201338. Video EEG monitoring outcomes.  \n10. L\u00f6scher W et al. Lancet Neurol 2013;12(10):993\u20131006. Ketogenic diet evidence.  \n11. McIntosh A et al. Epilepsia 2017;58(8):1236\u201349. Neuropsychology in epilepsy.  \n12. Harden CL et al. Neurology 2021;97(2):e231\u2013e241. Pregnancy and AED guidelines."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]